Tudor Investment Corp ET AL Acquires Shares of 53,572 Tango Therapeutics, Inc. $TNGX

Tudor Investment Corp ET AL bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 53,572 shares of the company’s stock, valued at approximately $450,000.

Several other hedge funds and other institutional investors have also bought and sold shares of TNGX. Legal & General Group Plc lifted its stake in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Tango Therapeutics by 44.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after buying an additional 2,907 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Tango Therapeutics by 78.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after buying an additional 3,452 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Tango Therapeutics by 13.7% during the 2nd quarter. Intech Investment Management LLC now owns 45,675 shares of the company’s stock worth $234,000 after buying an additional 5,518 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Tango Therapeutics by 461.3% in the third quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company’s stock valued at $65,000 after buying an additional 6,352 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TNGX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Wedbush increased their target price on shares of Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Guggenheim raised their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Mizuho lifted their price target on shares of Tango Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, March 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $18.00 price objective on shares of Tango Therapeutics in a research note on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.50.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $21.22 on Thursday. The stock’s 50-day moving average is $14.76 and its 200 day moving average is $10.97. Tango Therapeutics, Inc. has a one year low of $1.03 and a one year high of $21.82. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of -24.39 and a beta of 1.30.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, sell-side analysts expect that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Insider Transactions at Tango Therapeutics

In other news, insider Adam Crystal sold 12,000 shares of Tango Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $20.11, for a total value of $241,320.00. Following the completion of the sale, the insider owned 112,622 shares in the company, valued at $2,264,828.42. The trade was a 9.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barbara Weber sold 30,519 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the transaction, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. The trade was a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 145,884 shares of company stock valued at $1,965,942 in the last quarter. 7.50% of the stock is currently owned by company insiders.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.